Morning Headlines 5/6/15
Cognizant Earnings Top, Fueled By TriZetto Buy
Cognizant reports Q1 results: revenue up 20 percent to $2.9 billion, EPS $0.62 vs. $0.57, beating analyst estimates on both. The company’s stock price climbed 10.8 percent, to a record high $65.55, following the results.
Imprivata Achieves Revenue Growth of 32% for the First Quarter of 2015 and Raises Annual Guidance
Imprivata reports Q1 results: revenue up 32 percent to $25 million but still resulted in an overall net loss of $6.7 million, EPS –$0.28 vs. –$2.29, beating expectations for both.
In a New Yorker piece, Atul Gawande, MD discusses the tendency to overtreat patients in the US, citing a study suggesting that, every year, at least 25 percent of Medicare patients receive high-cost tests that are well known to be wasteful.
Apple will begin offering DNA testing to some iPhone owners to support current and future ResearchKit initiatives. UCSF and Mount Sinai Hospital are planning ResearchKit-based studies that involve DNA testing.
https://www.epicresearch.org/articles/many-patients-maintain-weight-loss-a-year-after-stopping-semaglutide-and-liraglutide https://www.epicresearch.org/articles/patients-with-higher-initial-bmis-and-greater-weight-loss-while-on-glp-1s-most-likely-to-maintain-or-continue-weight-loss-after-stopping-glp-1s Regaining the weight is a risk, but it seems many people with obesity maintain or even lose more…